assisting the body with handling stress, increasing energy, improving brain function, boosting antioxidant protection from free radicals, and maintaining an optimal metabolism
FDA staff stated the compound lacks sufficient information to know whether the drug would cause harm when administered to humans. The committees public docket drew approximately 1,860 comments before the July 23-24 hearing, reflecting broad interest from patients, clinicians, and compounding pharmacists
The exclusion criteria were alcohol consumption, consumption of vitamins or food supplements with antioxidants, report of infertility, and the use of contraceptives
Its most advanced use, the CagriSema combination, has produced late-stage trial data but remains under regulatory review